1. Home
  2. OMAB vs DFTX Comparison

OMAB vs DFTX Comparison

Compare OMAB & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

OMAB

Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

N/A

Current Price

$101.58

Market Cap

5.0B

ML Signal

N/A

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$28.37

Market Cap

4.0B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
OMAB
DFTX
Founded
1998
N/A
Country
Mexico
United States
Employees
N/A
N/A
Industry
Aerospace
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
4.0B
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
OMAB
DFTX
Price
$101.58
$28.37
Analyst Decision
Buy
Strong Buy
Analyst Count
7
19
Target Price
★ $117.13
$72.83
AVG Volume (30 Days)
79.2K
★ 1.5M
Earning Date
10-27-2026
11-09-2026
Dividend Yield
★ 5.40%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.75
N/A
Revenue Next Year
$9.00
N/A
P/E Ratio
$21.86
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$87.31
$14.62
52 Week High
$134.99
$49.70

Technical Indicators

Market Signals
Indicator
OMAB
DFTX
Relative Strength Index (RSI) 43.27 33.49
Support Level $96.33 $20.43
Resistance Level $104.04 $38.59
Average True Range (ATR) 2.46 1.85
MACD -0.95 -0.47
Stochastic Oscillator 3.44 0.90

Price Performance

Historical Comparison
OMAB
DFTX

About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS

Grupo Aeroportuario del Centro Norte SAB de CV operates, maintains and develops airports in the Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages hotels, industrial parks, and individual airports. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, and in Others.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: